Friday, June 27, 2014 3:22:45 PM
Interesting quote from ...cookie from yahoo finance:
"EDAP may be a medical equipment company but it greatly resembles a drug company in that they not only supply expensive equipment but are now furnishing a kit which must be used for each treatment using that equipment. The kit costs 900 euro, that's about $1250. The profit on these kits has been said to be substantial so we can assume it must be at least $500. If they were to have, say. 20,000 treatments per quarter that would be a profit of $10 million. We are looking at a gold mine here."
"EDAP may be a medical equipment company but it greatly resembles a drug company in that they not only supply expensive equipment but are now furnishing a kit which must be used for each treatment using that equipment. The kit costs 900 euro, that's about $1250. The profit on these kits has been said to be substantial so we can assume it must be at least $500. If they were to have, say. 20,000 treatments per quarter that would be a profit of $10 million. We are looking at a gold mine here."
Recent FOCL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2026 11:30:18 AM
- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy • GlobeNewswire Inc. • 05/29/2026 11:30:00 AM
- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference • GlobeNewswire Inc. • 05/21/2026 11:30:00 AM
- Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches • GlobeNewswire Inc. • 05/15/2026 10:30:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 05/14/2026 11:33:35 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/14/2026 11:32:39 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/14/2026 11:31:51 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 05/14/2026 11:30:29 AM
- EDAP | Focal One and Telix Announce Collaboration Focused on Robotic HIFU and Theranostics in Prostate Cancer • GlobeNewswire Inc. • 05/14/2026 11:30:00 AM
- EDAP | Focal One to Host Investor Day on June 1, 2026 • GlobeNewswire Inc. • 05/13/2026 08:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:05:24 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:05:04 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:04:42 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:04:17 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:03:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 10:03:23 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 08:03:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:30:20 AM
- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/01/2026 08:01:52 PM
- EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One® Robotic HIFU in Radiorecurrent Prostate Cancer • GlobeNewswire Inc. • 04/30/2026 12:30:00 PM
- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 • GlobeNewswire Inc. • 04/16/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:05:13 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/31/2026 08:55:52 PM
